Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma

GC33 is a humanized mAb against human glypican-3 (GPC3). In the first-in-human study carried out in the USA, GC33 was well tolerated and showed preliminary antitumor activity in patients with advanced hepatocellular carcinoma. This study aimed to assess the safety, tolerability, and pharmacokinetic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Ikeda, Masafumi, Ohkawa, Shinichi, Okusaka, Takuji, Mitsunaga, Shuichi, Kobayashi, Satoshi, Morizane, Chigusa, Suzuki, Ikue, Yamamoto, Shunsuke, Furuse, Junji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2014
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317809/
https://ncbi.nlm.nih.gov/pubmed/24521523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12368
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller